JP7121859B2 - 安息香酸塩または安息香酸誘導体を含む、抗n-メチル-d-アスパラギン酸受容体脳炎を予防または治療するための医薬組成物 - Google Patents
安息香酸塩または安息香酸誘導体を含む、抗n-メチル-d-アスパラギン酸受容体脳炎を予防または治療するための医薬組成物 Download PDFInfo
- Publication number
- JP7121859B2 JP7121859B2 JP2021526187A JP2021526187A JP7121859B2 JP 7121859 B2 JP7121859 B2 JP 7121859B2 JP 2021526187 A JP2021526187 A JP 2021526187A JP 2021526187 A JP2021526187 A JP 2021526187A JP 7121859 B2 JP7121859 B2 JP 7121859B2
- Authority
- JP
- Japan
- Prior art keywords
- benzoate
- pharmaceutical composition
- day
- subject
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Description
実施例
Claims (15)
- 有効量の安息香酸塩を含む、必要とする対象における抗N-メチル-D-アスパラギン酸受容体(NMDAR)脳炎を予防または治療するための医薬組成物であって、
前記の安息香酸塩は、抗NMDAR脳炎を予防または治療するために静脈内免疫グロブリンによる免疫療法と組み合わせて上記対象に投与されることを特徴とする、医薬組成物。 - 上記の安息香酸塩は、安息香酸ナトリウム、安息香酸カリウム、安息香酸カルシウム、または安息香酸マグネシウムである、請求項1に記載の医薬組成物。
- 上記の安息香酸塩は、安息香酸ナトリウムである、請求項1に記載の医薬組成物。
- 上記の抗NMDAR脳炎は、NMDARの機能低下によって引き起こされる、請求項1に記載の医薬組成物。
- 上記の安息香酸塩は、対象におけるNMDAR機能を増強または活性化する、請求項1に記載の医薬組成物。
- 上記の安息香酸塩は、200mg/日~2000mg/日の範囲の量で上記対象に投与される、請求項1に記載の医薬組成物。
- 上記の安息香酸塩は、400mg/日~1800mg/日の範囲の量で上記対象に投与される、請求項1に記載の医薬組成物。
- 上記の安息香酸塩は、450mg/日~1500mg/日の範囲の量で上記対象に投与される、請求項1に記載の医薬組成物。
- 上記の安息香酸塩は、500mg/日~1000mg/日の範囲の量で上記対象に投与される、請求項1に記載の医薬組成物。
- 上記の安息香酸塩は、1ヶ月間~2年間の期間範囲で上記対象に投与される、請求項1に記載の医薬組成物。
- 上記の安息香酸塩は、4週間~12ヶ月間の期間範囲で上記対象に投与される、請求項1に記載の医薬組成物。
- 上記の安息香酸塩は、抗NMDAR脳炎を予防または治療するために追加の有効成分と組み合わせて上記対象に投与される、請求項1に記載の医薬組成物。
- 上記の追加の有効成分は、抗精神病薬である、請求項12に記載の医薬組成物。
- 上記の安息香酸塩は、抗NMDAR脳炎を予防または治療するために追加の治療と組み合わせて上記対象に投与される、請求項1に記載の医薬組成物。
- 上記の追加の治療は、心理療法、電気けいれん療法(ECT)、血漿交換、ステロイドによるパルス療法、またはそれらの任意の組み合わせを含む、請求項14に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862698558P | 2018-07-16 | 2018-07-16 | |
US62/698,558 | 2018-07-16 | ||
PCT/MY2019/000025 WO2020017950A1 (en) | 2018-07-16 | 2019-07-16 | Benzoic acid or a salt thereof for use in preventing or treating anti-n-methyl-d-aspartate receptor encephalitis |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021530567A JP2021530567A (ja) | 2021-11-11 |
JP7121859B2 true JP7121859B2 (ja) | 2022-08-18 |
Family
ID=69165110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021526187A Active JP7121859B2 (ja) | 2018-07-16 | 2019-07-16 | 安息香酸塩または安息香酸誘導体を含む、抗n-メチル-d-アスパラギン酸受容体脳炎を予防または治療するための医薬組成物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210228515A1 (ja) |
EP (1) | EP3823609A4 (ja) |
JP (1) | JP7121859B2 (ja) |
KR (1) | KR102615988B1 (ja) |
CN (1) | CN112437661A (ja) |
AU (2) | AU2019304850B2 (ja) |
CA (1) | CA3102371A1 (ja) |
MY (1) | MY195960A (ja) |
TW (1) | TWI726355B (ja) |
WO (1) | WO2020017950A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4007574A4 (en) * | 2019-08-01 | 2023-08-02 | Aptinyx Inc. | METHODS OF TREATING DISORDERS ASSOCIATED WITH HIGH LEVELS OF ANTIBODIES INTERACTING WITH THE NMDA RECEPTOR |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014191992A1 (en) | 2013-05-28 | 2014-12-04 | Sarah Herzog Memorial Hospital-Ezrath Nashim | Autoimmune-induced glutamatergic receptor dysfunction methods and treatments |
-
2019
- 2019-07-15 TW TW108124912A patent/TWI726355B/zh active
- 2019-07-16 KR KR1020217000780A patent/KR102615988B1/ko active IP Right Grant
- 2019-07-16 EP EP19838008.1A patent/EP3823609A4/en active Pending
- 2019-07-16 US US17/258,180 patent/US20210228515A1/en active Pending
- 2019-07-16 JP JP2021526187A patent/JP7121859B2/ja active Active
- 2019-07-16 WO PCT/MY2019/000025 patent/WO2020017950A1/en unknown
- 2019-07-16 MY MYPI2020006680A patent/MY195960A/en unknown
- 2019-07-16 CN CN201980042941.2A patent/CN112437661A/zh active Pending
- 2019-07-16 AU AU2019304850A patent/AU2019304850B2/en active Active
- 2019-07-16 CA CA3102371A patent/CA3102371A1/en active Pending
-
2022
- 2022-02-16 AU AU2022201030A patent/AU2022201030B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014191992A1 (en) | 2013-05-28 | 2014-12-04 | Sarah Herzog Memorial Hospital-Ezrath Nashim | Autoimmune-induced glutamatergic receptor dysfunction methods and treatments |
Non-Patent Citations (4)
Title |
---|
Acta Neuropsychiatrica,2015年,27(3), pp.159-167 |
Biological Psychiatry,2015年,77(6),pp.e27-e29 |
JAMA Psychiatry,2013年,70(12),pp.1267-1275 |
Neuroimmunology and Neuroinflammation,2016年,3,pp.189-191 |
Also Published As
Publication number | Publication date |
---|---|
KR102615988B1 (ko) | 2023-12-20 |
CA3102371A1 (en) | 2020-01-23 |
WO2020017950A1 (en) | 2020-01-23 |
AU2019304850A1 (en) | 2020-11-26 |
MY195960A (en) | 2023-02-27 |
JP2021530567A (ja) | 2021-11-11 |
TW202011949A (zh) | 2020-04-01 |
AU2022201030B2 (en) | 2023-10-05 |
AU2019304850B2 (en) | 2022-06-02 |
TWI726355B (zh) | 2021-05-01 |
CN112437661A (zh) | 2021-03-02 |
AU2022201030A1 (en) | 2022-03-10 |
EP3823609A4 (en) | 2022-04-20 |
KR20210021356A (ko) | 2021-02-25 |
EP3823609A1 (en) | 2021-05-26 |
US20210228515A1 (en) | 2021-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11207279B2 (en) | Application of R-ketamine and salt thereof as pharmaceuticals | |
TWI638654B (zh) | 用以治療中樞神經系統疾病之包含苯甲酸鹽化合物及鞣酸的組合物 | |
US20090048181A1 (en) | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis | |
US9248123B2 (en) | Methods of providing weight loss therapy in patients with major depression | |
JP6951976B2 (ja) | 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および/または代謝疾患の処置のための、脳由来神経栄養因子(bdnf)の誘導された発現 | |
JP2017537089A5 (ja) | ||
KR20140121475A (ko) | 특발성 염증성 근질환의 예방 또는 치료제 | |
JP2017510607A5 (ja) | ||
AU2022201030B2 (en) | Benzoic acid or a salt and derivative thereof for use in preventing or treating anti-n-methyl-d-aspartate receptor encephalitis | |
WO2016176609A1 (en) | Methods of treating prader-willi syndrome | |
JP2013500943A5 (ja) | ||
TWI686192B (zh) | 含有鞣酸的組合物及其用途 | |
JP2019001830A (ja) | 医薬 | |
JP2004002353A (ja) | 医薬組成物 | |
CA2846768A1 (en) | Combinations comprising a s1p receptor modulator | |
JP2020037581A (ja) | 多発性硬化症を処置するための併用療法 | |
JP2004175786A (ja) | I型アレルギー疾患治療用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210205 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210205 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220315 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220526 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220526 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220712 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220805 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7121859 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |